证券代码：300363 证券简称：博腾股份 博腾股份投资者关系活动记录表 编号：00320200330 | --- | --- | --- | |-------------------------|-----------------------------------------|----------------------------------------------------| | | | | | | □特定对象调研 □分析师会议 | | | | □媒体采访 | □业绩说明会 | | 投资者关系活 | □新闻发布会 □路演活动 | | | 动类别 | □现场参观 | □电话通讯 | | | ■其他 （分析师电话会议） | | | 参与单位名称 及人员姓名 | 54 家机构 80 | 名参与人员，详见附件清单。 | | 时间 | 2020 年 3 月 30 日 | | | | 地点 电话会议 | | | | 董事长 总经理 | 居年丰 | | 上市公司接待 人员姓名 | 副总经理 财务负责人 副总经理 吉耀辉 | 孙敏 | | | 证券事务代表 皮薇 | | | | 公司与投资者交流情况如下： | | ...

证券代码：300363 证券简称：博腾股份 编号：00220200330 | --- | --- | --- | --- | |-----------------------|------------------------------------------------------------|------------------------------------------------------|----------------------------| | | | | | | | □特定对象调研 □分析师会议 | | | | | □媒体采访 | ■业绩说明会 | | | 投资者关系活动 类别 | □新闻发布会 □路演活动 | | | | | □现场参观 | □电话通讯 | | | | □其他 | （请文字说明其他活动内容） | | | 参与单位名称及 | 华西证券 崔文亮，海通证券 | 范国钦，安信证券 | 李浩治，国 | | 人员姓名 | 金证券 王班等约 200 | 位投资者 | | | 时间 | 2020 年 3 月 30 日 | | | | 地点 " | Zoom "及"路演中"线上会议 | ...

证券代码：300363 证券简称：博腾股份 编号：00820200902 | --- | --- | --- | |--------------|------------------------------|-------------------------------------------------------------------------------------------------------------| | | | | | | | ■特定对象调研 □分析师会议 | | 投资者关系活 | □媒体采访 | □业绩说明会 | | 动类别 | | □新闻发布会 □路演活动 | | | □现场参观 | □电话通讯 | | | □其他 | | | | | 光大证券：林小伟，刘锡源；国元证券：刘巧；中银国际证 | | | | 券：邓周宇；川财证券：王志强；重庆德睿恒丰资产管理有 | | 参与单位名称 | | 限公司：周义博、何小华；北京正格资本管理有限公司：张 | | 及人员姓名 | | 诚；深圳市前海德毅资产管理有限公司：荣富志；坚果投资： 盖伟伟；深圳长润君和资产管理有限公司：龚显胜；广州中 | ...

证券代码：300363 证券简称：博腾股份 编号：00620200529 | --- | --- | --- | |------------------------------|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | | ■特定对象调研 □分析师会议 | | 投资者关系活 | □媒体采访 | □业绩说明会 | | 动类别 | | □新闻发布会 □路演活动 | | | □现场参观 | □电话通讯 | | | □其他 | | | | | 国盛证券：张金洋、胡偌碧；中金基金：兰兰；国金资管： | | | | 朱明睿；大成基金：向秋静；星石投资：王雪刚；博时基金： 孔令熙；华商基金：孙蔚；中庚基金：郑宁；混沌投资：张 | | 参与单位名称 及人员姓名 | | 肖星、张昕 ...

证券代码：300363 证券简称：博腾股份 博腾股份投资者关系活动记录表 编号：00920191205 | --- | --- | --- | |-------------------------|------------------------------------|----------------------------------------------------------| | | | | | | ■特定对象调研 □分析师会议 | | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | | □现场参观 | □电话通讯 | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | | 弘则弥道（上海）投资咨询有限公司：郭望葳 | | 时间 | 2019 年 12 月 05 日 | | | 地点 | 公司 2-1 会议室 | | | 上市公司接待人 员姓名 | 证券事务代表皮薇，董事会办公室陈靓 | | | | | | | | 公司与投资者交流情况如下： | | | | Q1 ：公司战略发展差异化在哪里？ | | ...

证券代码：300363 证券简称：博腾股份 编号：00820191128 | --- | --- | --- | |-----------------------------|-------------------------------------|--------------------------------------------------------| | | | | | | ■特定对象调研 □分析师会议 | | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | | □现场参观 | □电话通讯 | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | 国盛证券：张金洋 中信建投证券：俞冰 | 中银基金：陈军、刘潇、刘浩宇、陈哲、王方舟、杨雷 | | 时间 | 2019 年 11 月 28 日 | | | 地点 公司 | 2-1 会议室 | | | 上市公司接待人 员姓名 | | 副总经理吉耀辉，证券事务代表皮薇，董事会办公室陈靓 | | | 公司与投资者交流情况如下： | | | | Q1 | ：请介绍一下 ...

证券代码：300363 证券简称：博腾股份 博腾股份投资者关系活动记录表 编号：00720191112 | --- | --- | --- | |-------------------------|--------------------------------------|----------------------------------------------------| | | | | | | ■特定对象调研 □分析师会议 | | | | □媒体采访 | □业绩说明会 | | 投资者关系活动 类别 | □新闻发布会 □路演活动 | | | | □现场参观 | □电话通讯 | | | □其他 （请文字说明其他活动内容） | | | 参与单位名称及 人员姓名 | 北京源乐晟资产管理有限公司：欧阳明 | | | 时间 | 2019 年 11 月 12 日 | | | 地点 公司 | 2 楼视频会议室 | | | 上市公司接待人 员姓名 | 证券事务代表皮薇、董事会办公室汪星星 | | | | 公司与投资者交流情况如下： | | | | Q1 ： 2019 年前三季度，公司 | CRO 业务中 J-STAR ...

证券代码：300363 证券简称：博腾股份 | --- | --- | --- | --- | |-------------------------|----------------------------------|--------------------------------------------------------|--------------------------------| | | | 编号：00320190821 | | | | █特定对象调研 □分析师会议 | | | | | □媒体采访 | □业绩说明会 | | | 投资者关系活 | □新闻发布会 □路演活动 | | | | 动类别 | □现场参观 | □电话通讯 | | | | □其他 | （请文字说明其他活动内容） | | | 参与单位名称 及人员姓名 | 信达证券 周贤珮 | | | | 时间 2019 | 年 08 月 21 日 | | | | 地点 水土 | 2-1 会议室 | | | | 上市公司接待 | 皮薇 证券事务代表 | | | | 人员姓名 | 陈靓 投资者关系主管 | | | | | 一、证券事务代表介绍公 ...

Group 1: Business Transformation and Growth - The company has over 400 active projects across various stages from clinical to market, and a client base of over 300, which are crucial for future growth [3] - The CRO and API businesses are on a growth trajectory, with short-term growth reflected in project numbers and long-term growth expected from increased business flow and client retention [3] - The management is focused on enhancing organizational capabilities and core competitiveness within the CDMO sector, anticipating stable future business development [3] Group 2: Human Resources and Efficiency - The company has approximately 1,800 employees, which is half the number compared to peers, leading to higher per capita revenue output due to different asset structures and business attributes [3] - Despite a modest increase in total personnel, the number of R&D staff has doubled, and there has been significant growth in sales and marketing personnel [3] - The company delivered 44 API projects in 2018 and 34 in the first half of 2019, indicating a strong operational capacity in the CMO business [3][4] Group 3: Product Pipeline and Market Strategy - The largest single product in the pipeline generates annual revenue of around 100 million RMB, with products achieving over 5 million USD in annual sales considered high-value [4] - The company is cautious about high client and product concentration risks, ensuring a diverse product pipeline to support stable development [4] - The company maintains an open yet cautious approach towards acquisitions, focusing on internal development and potential small-scale acquisitions for unique technological capabilities [4]

Group 1: Company Overview - As of Q3 2019, the total number of employees at Boteng Co. reached 1,999, with 364 in R&D, serving over 300 clients [3] - The company operates two main production bases located in Chongqing and Yichun, with a total capacity of approximately 1,191 cubic meters [3] - The Chongqing facility has 10 workshops with a capacity of nearly 700 cubic meters, while the Yichun facility has 6 workshops with a capacity of about 491 cubic meters [3] Group 2: Financial Performance - In the first three quarters of 2019, Boteng Co. achieved a revenue of 1.08 billion yuan, representing a year-on-year growth of approximately 30% [4] - The net profit for the same period was 140 million yuan, with a year-on-year increase of 39% [4] - The gross profit margin improved to 37.5%, an increase of about 3.6 percentage points compared to the previous year [4] Group 3: Business Segments - The CRO business generated revenue of 305 million yuan in the first three quarters, with 138 products contributing to the income [3] - The European market accounted for 39% of sales, while North America represented 26%, marking significant growth in these regions [3] - The product pipeline included 238 products sold, with 108 being new products and 138 being existing products [3] Group 4: R&D and Capacity Expansion - The company plans to increase R&D personnel by 100 each year over the next two years [4] - In 2019, investments in crystallization and enzyme catalysis technologies amounted to approximately 10 million yuan and 20 million yuan, respectively [5] - The company aims to enhance production efficiency, with a 60% increase in production batches per week compared to the previous year [4] Group 5: Strategic Direction - Boteng Co. is focusing on a CDMO model that emphasizes "traffic × conversion × monetization," integrating CRO and CMO services to enhance monetization capabilities [5] - The company recognizes the importance of understanding industry cycles, particularly in oncology and rare diseases, to identify growth opportunities [6] - The acquisition of J-STAR has expanded its team from 40 to 98 members, enhancing its capabilities in the U.S. market [6]